CAPLIPOINT

Caplin Point Laboratories reported strong Q4FY25.....

Caplin Point Laboratories reported strong Q4FY25 and full-year FY25 results. In Q4FY25, revenue rose 10.9% YoY to Rs 502.5 crore, with a gross margin of 60% and EBITDA up 19.2% to Rs 193.8 crore. PAT increased 19.8% to Rs 145.3 crore, and the EBITDA margin improved to 36.7%. For FY25, total revenue grew 15.5% to Rs 2,034 crore, and PAT rose 17.3% to Rs 541 crore. The company maintained a healthy EBITDA margin of 36.5%, and EPS increased 17.2% to Rs 70.57. Operational cash flow rose to Rs 432.39 crore, and free cash reserves stood at Rs 1,180 crore with liquid assets at Rs 2,148 crore. The US market EBITDA grew significantly by 71% YoY to Rs 102 crore. Management expressed optimism about future growth, driven by US expansion, API verticals, and asset-light strategies in China for biosimilars and peptide sourcing.